News & SEC Filings

View the latest news and SEC filings

News

Approximately $36 million and $42 million net product sales of Ohtuvayre for the fourth quarter and full year 2024, respectively More than 3,500 unique prescribers and over 16,000 prescriptions filled in 2024 across a broad COPD population Approximately 45% of Tier 1 HCPs prescribed Ohtuvayre

LONDON and RALEIGH, N.C., Nov. 19, 2024 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that senior management will present a company overview at the following conferences in December 2024: Piper Sandler 36 th Annual Healthcare Conference Date:

LONDON and RALEIGH, N.C., Nov. 05, 2024 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that senior management will present a company overview at the Jefferies London Healthcare Conference on Tuesday, November 19, 2024, at 6:30 a.m. ET / 11:30 a.m.

Ohtuvayre™  (ensifentrine) launch recorded Q3 net sales of $5.6 million and  October net sales exceeded Q3 Through October more than 2,200 unique prescribers and more than 5,000 prescriptions filled across a broad COPD population Pipeline expansion continues: Phase 2 programs enrolling Conference

SEC Filings

Date Form Filing Group

January 30, 2017

mendment to a previously filed DRS

DRS/A

Registration Statements

December 21, 2016

UPLOAD

UPLOAD

Other

PDF

November 23, 2016

Draft registration statement submitted by Emerging Growth Company under Securities Act Section 6(e) or by Foreign Private Issuer under Division of Corporation Finance policy

DRS

Registration Statements

July 20, 2016

D

Other

Developing novel therapeutics for respiratory diseases

Verona Pharma (Nasdaq:VRNA) is focused on delivering our strategy and creating value for shareholders.